Heart Failure

View the latest content related to this topic

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

(UPDATED) The drug is often used not because it’s optimal, but because it’s cheap, says one group. That shouldn’t be the case.

Michael O'Riordan

August 01, 2025

Slides

See all

Presentation ACC 2025

FAIR-HF2 Trial: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality

Presenter: Stefan D. Anker

March 30, 2025

Presentation ACC 2025

The MIGHTy-Heart Randomized Clinical Trial

Presenter: Ruth Masterson Creber

March 30, 2025

Presentation ACC 2025

Liberal Fluid Intake versus Fluid Restriction in Chronic Heart Failure: The FRESH-UP Study

Presenter: Roland R. Van Kimmenade

March 30, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

Presentation THT 2025

Implantable Cardiac Patch Continuously Monitors Inflammation and Acute Heart Failure Biomarkers In Vivo and Ex Vivo

Presenter: Devleena Das

February 13, 2025

News

See all

News Daily News

Conduction-System Pacing Successful as First-line Option for AV Block: CSPACE

By Todd Neale

August 19, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

By Yael L. Maxwell

August 18, 2025

News Daily News

TEER May Surpass Medical Therapy in High-risk Atrial FMR Patients

By Caitlin E. Cox

August 13, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

By Michael O'Riordan

August 01, 2025

News Daily News

HF Risks Stick Around Even When Ejection Fraction Improves

By Todd Neale

August 01, 2025

ACC 2025

March 29

March 31, 2025

CTO 2025

February 28

March 01, 2025

THT 2025

February 11

February 13, 2025

Videos on This Topic

See all

Advertisement

Heart Failure

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Slides

FAIR-HF2 Trial: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality

The MIGHTy-Heart Randomized Clinical Trial

Liberal Fluid Intake versus Fluid Restriction in Chronic Heart Failure: The FRESH-UP Study

Dapagliflozin after Transcatheter Aortic Valve Implantation

Implantable Cardiac Patch Continuously Monitors Inflammation and Acute Heart Failure Biomarkers In Vivo and Ex Vivo

News

Conduction-System Pacing Successful as First-line Option for AV Block: CSPACE

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

TEER May Surpass Medical Therapy in High-risk Atrial FMR Patients

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

HF Risks Stick Around Even When Ejection Fraction Improves

More on This Topic

Conference Coverage

ACC 2025

CTO 2025

THT 2025

Videos on This Topic

Advertisement

Heart Failure

Slides

News

More on This Topic

Conference Coverage

Videos on This Topic

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content